roche holding ag-genusschein
(ROG:SIX Swiss Ex)
Transactions by ROCHE HOLDING AG-GENUSSCHEIN (ROG) in the last 6 months
Roche Holding AG (SWX:ROG) acquired CAPP Medical on April 13, 2015.
Roche Holding AG (SWX:ROG) acquired Signature Diagnostics AG from VRP Venture Capital Rheinland-Pfalz GmbH & Co. I managed by EVP Capital Management AG, KfW Mittelstandsbank, Investment Arm, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, BC Brandenburg Capital GmbH and others on February 9, 2015. Signature will be integrated into Roche Sequencing Unit and will continue to focus on expanding its innovative genomic signature portfolio.
EVP Capital Management AG
GoodVent Beteiligungsmanagement GmbH & Co.KG
IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH
IBG Risikokapitalfonds I GmbH & Co. KG
KfW Mittelstandsbank, Investment Arm
Roche Holding AG (SWX:ROG) entered into agreement to acquire Trophos SA from ACG Management, Turenne Capital Partenaires, Association Française contre les Myopathies, Vesale Partners, OTC Agregator, Amundi Private Equity Funds, Sofipaca SCR ans about sixty employees, relatives and the founders for €470 million on January 16, 2015. Under the terms of the agreement, Trophos's shareholders will receive an upfront cash payment of €120 million, plus additional contingent ...
Amundi Private Equity Funds
Association Française contre les Myopathies
Turenne Capital Partenaires
Roche Holding AG (SWX:ROG) acquired BINA Technologies Inc. from Sierra Ventures, Columbus Nova Technology Partners, RONA Holdings, LLC, Streamlined Ventures, Signatures Capital, LLC and other shareholders on December 19, 2014. Bina will be integrated into Roche Sequencing Unit in first quarter of 2015.
Columbus Nova Technology Partners
RONA Holdings, LLC
Signatures Capital, LLC
Roche Holding AG (SWX:ROG) agreed to acquire Dutalys GmbH for approximately $490 million on December 18, 2014. Under the terms of the agreement, Roche will make an upfront cash payment of $133.8 million to shareholders and make additional contingent payments of up to $355 million based on the achievement of certain predetermined milestones. The transaction is positive for Roche in terms of potentially allowing it to strengthen development of therapeutic antibodies - ...
|Gilead Sciences Inc||$113.94 USD||-0.14|
|Johnson & Johnson||$99.98 USD||-0.06|
|Novartis AG||SFr.96.30 CHF||-1.10|
|Pfizer Inc||$34.49 USD||-0.07|
|View Industry Companies|